Trial Profile
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination With Nivolumab in Patients With Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 20 Mar 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Telaglenastat (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Calithera Biosciences
- 21 Feb 2023 Status changed from completed to discontinued.
- 29 Jan 2021 Status changed from active, no longer recruiting to completed.
- 28 Jan 2020 Planned End Date changed from 1 Jun 2019 to 1 Jun 2020.